Immune Evasion by Murine Melanoma Mediated through CC Chemokine Receptor-10

Journal of Experimental Medicine

Volumn 198, Issue 9, 2003, Pages 1337-1347

  Murakami, Takashi ^a   Cardones, Adela R ^a   Finkelstein, Steven E ^a   Restifo, Nicholas P ^a   Klaunberg, Brenda A ^c   Nestle, Frank O ^b   Castillo, S Sianna ^a   Dennis, Phillip A ^a   Hwang, Sam T ^a,d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^c UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^d Bldg 10 ^*  (United States)

Author keywords

Cancer; Cell signaling; Chemokine receptor; Metastasis

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR10; FAS ANTIGEN; LUCIFERASE; MELANOMA ANTIGEN; MESSENGER RNA; NEUTRALIZING ANTIBODY; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; FEMALE; HUMAN; IMMUNITY; IN VITRO STUDY; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CROSS LINKING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR GROWTH;

AGED; ANIMALS; APOPTOSIS; BASE SEQUENCE; BLOTTING, WESTERN; DNA PRIMERS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; RECEPTORS, CHEMOKINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 0242611008     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.20030593     Document Type: Article

References (44)

1. Dreiling, L., S. Hoffman, and W.A. Robinson. 1996. Melanoma: epidemiology, pathogenesis, and new modes of treatment. Adv. Intern. Med. 41:553-604.
2. Khong, H.T., and N.P. Restifo. 2002. Natural selection of tumor variants in the generation of "tumor escape" phenotypes. Nat. Immunol. 3:999-1005.
3. Maecker, H.L., Z. Yun, H.T. Maecker, and A.J. Giaccia. 2002. Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell. 2:139-148.
4. Strand, S., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med. 2:1361-1366.
5. Bullani, R.R., B. Huard, I. Viard-Leveugle, H.R. Byers, M. Irmler, J.H. Saurat, J. Tschopp, and L.E. French. 2001. Selective expression of FLIP in malignant melanocytic skin lesions. J. Invest. Dermatol. 117:360-364.
6. Rossi, D., and A. Zlotnik. 2000. The biology of chemokines and their receptors. Annu. Rev. Immunol. 18:217-242.
7. Balkwill, F. 2003. Chemokine biology in cancer. Semin. Immunol. 15:49-55.
8. Müller, A., B. Homey, H. Soto, N. Ge, D. Catron, M.E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S.N. Wagner, et al. 2001. Involvement of chemokine receptors in breast cancer metastasis. Nature. 410:50-56.
9. Murakami, T., W. Maki, A.R. Cardones, H. Fang, A.T. Kyi, F. Nestle, and S.T. Hwang. 2002. Expression of CXC chemokine receptor (CXCR)-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. Cancer Res. 62:7328-7334.
10. Wiley, H., E.B. Gonzalez, W. Maki, M. Wu, and S.T. Hwang. 2001. Expression of CC chemokine receptor-7 (CCR7) and regional lymph node metastasis of B16 murine melanoma. J. Natl. Cancer Inst. 93:1638-1643.
11. Mashino, K., N. Sadanaga, H. Yamaguchi, F. Tanaka, M. Ohta, K. Shibuta, H. Inoue, and M. Mori. 2002. Expression of chemokine receptor CCR7 is associated with lymph node metastasis of gastric carcinoma. Cancer Res. 62:2937-2941.
12. Jannin, D.I., M. Rits, D. Bota, N. Gerard, G.J. Graham, I.C. Lewis, and C. Gerard. 2000. Cutting edge: Identification of the orphan receptor G-protein-coupled receptor 2 as CCR10, a specific receptor for the chemokine ESkine. J. Immunol. 164:3460-3464.
13. Homey, B., W. Wang, H. Soto, M. Buchanan, A. Wiesenborn, D. Catron, A. Muller, T. McClanahan, M.C.D. Nosjean, R. Orozco, et al. 2000. The orphan chemokine receptor G protein-coupled receptor-2 (GPR-2, CCR10) binds the skin-associated chemokine CCL27 (CTACK/ALP/ILC). J. Immunol. 164:3465-3470.
14. Morales, J., B. Homey, A.P. Vicari, S. Hudak, E. Oldham, J. Hedrick, R. Orozco, N.G. Copeland, N.A. Jenkins, L.M. McEvoy, et al. 1999. CTACK, a skin-associated chemokine that preferentially attracts skin-homing memory T cells. Proc. Natl. Acad. Sci. USA. 96:14470-14475.
15. Wang, W., H. Soto, E.R. Oldham, M.E. Buchanan, B. Homey, D. Catron, N. Jenkins, N.G. Copeland, D.J. Gilbert, N. Nguyen, et al. 2000. Identification of a novel chemokine (CCL28), which binds CCR10 (GPR2). J. Biol. Chem. 275:22313-22323.
16. Homey, B., H. Alenius, A. Muller, H. Soto, E.P. Bowman, W. Yuan, L. McEvoy, A.I. Lauerma, T. Assmann, E. Bunemann, et al. 2002. CCL27-CCR10 interactions regulate T cell-mediated skin inflammation. Nat. Med. 8:157-165.
17. Reiss, Y., A.E. Proudfoot, C.A. Power, J.J. Campbell, and E.C. Butcher. 2001. CC chemokine receptor (CCR)4 and the CCR10 ligand cutaneous T cell-attracting chemokine (CTACK) in lymphocyte trafficking to inflamed skin. J. Exp. Med. 194:1541-1547.
18. Takahashi, T., M. Tanaka, C.I. Brannan, N.A. Jenkins, N.G. Copeland, T. Suda, and S. Nagata. 1994. Generalized lymphoproliferative disease in mice, caused by a point mutation in the Fas ligand. Cell. 76:969-976.
19. Fidler, I.J. 1973. Selection of successive tumour lines for metastasis. Nature (New Biol.). 242:148-149.
20. West, K.A., J. Brognard, A.S. Clark, I.R. Linnoila, X. Yang, S.M. Swain, C. Harris, S. Belinsky, and P.A. Dennis. 2003. Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. J. Clin. Invest. 111:81-90.
21. Schneider, P., N. Holler, J.L. Bodmer, M. Hahne, K. Frei, A. Fontana, and J. Tschopp. 1998. Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity. J. Exp. Med. 187:1205-1213.
22. Overwijk, W.W., A. Tsung, K.R. Irvine, M.R. Parkhurst, T.J. Goletz, K. Tsung, M.W. Carroll, C. Liu, B. Moss, S.A. Rosenberg, and N.P. Restifo. 1998. gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-affinity, altered peptide ligand. J. Exp. Med. 188:277-286.
23. + T cells. J. Exp. Med. 198:569-580.
24. Peter, I., A. Mezzacasa, P. LeDonne, R. Dummer, and S. Hemmi. 2001. Comparative analysis of immunocritical melanoma markers in the mouse melanoma cell lines B16, K1735 and S91-M3. Melanoma Res. 11:21-30.
25. Bohm, W., S. Thoma, F. Leithauser, P. Moller, R. Schirmbeck, and J. Reimann. 1998. T cell-mediated, IFN-gamma-facilitated rejection of murine B16 melanomas. J. Immunol. 161:897-908.
26. Mullbacher, A., M. Lobigs, R.T. Hla, T. Tran, T. Stehle, and M.M. Simon. 2002. Antigen-dependent release of IFN-gamma by cytotoxic T cells up-regulates Fas on target cells and facilitates exocytosis-independent specific target cell lysis. J. Immunol. 169:145-150.
27. van den Brink, M.R., E. Moore, K.J. Horndasch, J.M. Crawford, G.F. Murphy, and S.J. Burakoff. 2000. Fas ligand-deficient gld mice are more susceptible to graft-versus-host-disease. Transplantation. 70:184-191.
28. Schumacher, T.N., M.T. Heemels, J.J. Neefjes, W.M. Kast, C.J. Melief, and H.L. Ploegh. 1990. Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell. 62:563-567.
29. Wong, M.M., and E.N. Fish. 2003. Chemokines: attractive mediators of the immune response. Semin. Immunol. 15:5-14.
30. Gibson, S., S. Tu, R. Oyer, S.M. Anderson, and G.L. Johnson. 1999. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J. Biol. Chem. 274:17612-17618.
31. Kalechman, Y., G. Strassmann, M. Albeck, and B. Sredni. 1998. Up-regulation by ammonium trichloro(dioxoethylene-0,0′) tellurate (AS101) of Fas/Apo-1 expression on B16 melanoma cells: implications for the antitumor effects of AS101. J. Immunol. 161:3536-3542.
32. Avent, J., C. Vervaert, and H.F. Seigler. 1979. Non-specific and specific active immunotherapy in a B16 murine melanoma system. J. Surg. Oncol. 12:87-96.
33. Tsai, V., S. Southwood, J. Sidney, K. Sakaguchi, Y. Kawakami, E. Appella, A. Sette, and E. Celis. 1997. Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary in vitro immunization with peptide-pulsed dendritic cells. J. Immunol. 158:1796-1802.
34. + T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl. Acad. Sci. USA. 99:16168-16173.
35. Ochsenbein, A.F., S. Sierro, B. Odermatt, M. Pericin, U. Karrer, J. Hermans, S. Hemmi, H. Hengartner, and R.M. Zinkernagel. 2001. Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction. Nature. 411:1058-1064.
36. Nestle, F.O., S. Alijagic, M. Gilliet, Y. Sun, S. Grabbe, R. Dummer, G. Burg, and D. Schadenforf. 1998. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4:328-332.
37. Vivanco, I., and C.L. Sawyers. 2002. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat. Rev. Cancer. 2:489-501.
38. Bunn, P.A., Jr., and W. Franklin. 2002. Epidermal growth factor receptor expression, signal pathway, and inhibitors in non-small cell lung cancer. Semin. Oncol. 29:38-44.
39. Stein, J.V., A. Rot, Y. Luo, M. Narasimhaswamy, H. Nakano, M.D. Gunn, A. Matsuzawa, E.J.Q.M.E. Dorf, and U.H. von Andrian. 2000. The CC chemokine thymus-derived chemotactic agent 4 (TCA-4, secondary lymphoid tissue chemokine, 6Ckine, Exodus-2) triggers lymphocyte function-associated antigen 1-mediated arrest of rolling T lymphocytes in peripheral lymph node high endothelial venules. J. Exp. Med. 191:61-75.
40. Gortz, A., R.J. Nibbs, P. McLean, D. Jarmin, W. Lambie, J.W. Baird, and G.J. Graham. 2002. The chemokine ESkine/CCL27 displays novel modes of intracrine and paracrine function. J. Immunol. 169:1387-1394.
41. Youn, B.S., K.Y. Yu, J. Oh, J. Lee, T.H. Lee, and H.E. Broxmeyer. 2002. Role of the CC Chemokine receptor 9/TECK 6interaction in apoptosis. Apoptosis. 7:271-276.
42. Boehme, S.A., F.M. Lio, D. Maciejewski-Lenoir, K.B. Bacon, and P.J. Conlon. 2000. The chemokine fractalkine inhibits Fas-mediated cell death of brain microglia. J. Immunol. 165:397-403.
43. Peled, A., I. Petit, O. Kollet, M. Magid, T. Ponomaryov, T. Byk, A. Nagler, H. Ben-Hur, A. Many, L. Shultz, et al. 1999. Dependence of human stem cell engraftment and repopulation of NOD/SCID mice on CXCR4. Science. 283:845-848.
44. Vlahakis, S.R., A. Villasis-Keever, T. Gomez, M. Vanegas, N. Vlahakis, and C.V. Paya. 2002. G protein-coupled chemokine receptors induce both survival and apoptotic signaling pathways. J. Immunol. 169:5546-5554.